Search Results - "Beddingfield, Frederick C."

ATX-101 for reduction of submental fat: A phase III randomized controlled trial by Humphrey, Shannon, MD, Sykes, Jonathan, MD, Kantor, Jonathan, MD, MSCE, MA, Bertucci, Vince, MD, Walker, Patricia, MD, PhD, Lee, Daniel R., MS, Lizzul, Paul F., MD, PhD, MPH, MBA, Gross, Todd M., PhD, Beddingfield, Frederick C., MD, PhD

“…Background ATX-101, an injectable form of deoxycholic acid, causes adipocytolysis when injected subcutaneously into fat. Objective We sought to evaluate the…”
Get full text

Eyelash growth in subjects treated with bimatoprost: A multicenter, randomized, double-masked, vehicle-controlled, parallel-group study by Smith, Stacy, MD, Fagien, Steven, MD, Whitcup, Scott M., MD, Ledon, Fred, BS, Somogyi, Christine, RN, Weng, Emily, ScD, Beddingfield, Frederick C., MD, PhD

“…Background Bimatoprost 0.03% is associated with increased growth and prominence of eyelashes. Objective We sought to compare the safety and efficacy of…”
Get full text

REFINE-1, a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial With ATX-101, an Injectable Drug for Submental Fat Reduction by Jones, Derek H, Carruthers, Jean, Joseph, John H, Callender, Valerie D, Walker, Patricia, Lee, Daniel R, Subramanian, Meenakshi, Lizzul, Paul F, Gross, Todd M, Beddingfield, 3rd, Frederick C

“…ATX-101, an injectable form of deoxycholic acid, is approved in the United States and Canada for submental fat (SMF) reduction. To report results of REFINE-1,…”
Get full text

Overview of ATX-101 (Deoxycholic Acid Injection): A Nonsurgical Approach for Reduction of Submental Fat by Dayan, Steven H, Humphrey, Shannon, Jones, Derek H, Lizzul, Paul F, Gross, Todd M, Stauffer, Karen, Beddingfield, 3rd, Frederick C

“…In 2015, ATX-101 (deoxycholic acid injection; Kybella in the United States and Belkyra in Canada; Kythera Biopharmaceuticals, Inc., Westlake Village, CA [an…”
Get full text

Efficacy and Safety of OnabotulinumtoxinA for Treating Crowʼs Feet Lines Alone or in Combination With Glabellar Lines: A Multicenter, Randomized, Controlled Trial by Moers-Carpi, Marion, Carruthers, Jean, Fagien, Steven, Lupo, Mary, Delmar, Henry, Jones, Derek, Somogyi, Christine, Lee, Elisabeth, Lei, Xiaofang, MacKinnon, Suzanne, Davis, Paula G, Yalamanchili, Ramana, Campo, Antoinette, Beddingfield, Frederick C

“…BACKGROUNDThis was the second study in a Phase 3 program treating crowʼs feet lines (CFL) with onabotulinumtoxinA. OBJECTIVETo evaluate the efficacy and safety…”
Get full text

The Melanoma Epidemic: Res Ipsa Loquitur by Beddingfield, Frederick C.

“…Learning Objectives After completing this course, the reader will be able to: Describe the factors suggesting the melanoma epidemic is real and not artificial…”
Get full text

Management of Patient Experience With ATX-101 (Deoxycholic Acid Injection) for Reduction of Submental Fat by Dover, Jeffrey S, Kenkel, Jeffrey M, Carruthers, Alastair, Lizzul, Paul F, Gross, Todd M, Subramanian, Meenakshi, Beddingfield, 3rd, Frederick C

“…ATX-101 (deoxycholic acid injection; Kythera Biopharmaceuticals, Inc., Westlake Village, CA [an affiliate of Allergan plc, Dublin, Ireland]) was recently…”
Get full text

Duration of wrinkle correction following repeat treatment with Juvéderm hyaluronic acid fillers by Smith, Stacy R, Jones, Derek, Thomas, Jane A, Murphy, Diane K, Beddingfield, Frederick C. III

“…Many patients elect to have repeat treatments with hyaluronic acid dermal fillers to maintain wrinkle correction, but the clinical performance of these…”
Get full text

Efficacy and Safety of ATX-101 by Treatment Session: Pooled Analysis of Data From the Phase 3 REFINE Trials by Dayan, Steven H, Schlessinger, Joel, Beer, Kenneth, Donofrio, Lisa M, Jones, Derek H, Humphrey, Shannon, Carruthers, Jean, Lizzul, Paul F, Gross, Todd M, Beddingfield, Frederick C, Somogyi, Christine

“…Abstract Background ATX-101 (deoxycholic acid injection) is the only injectable drug approved for submental fat (SMF) reduction. In the phase 3 REFINE trials,…”
Get full text

Dose response with onabotulinumtoxinA for post-stroke spasticity: A pooled data analysis by Yablon, Stuart A., Brin, Mitchell F., VanDenburgh, Amanda M., Zhou, Jihao, Garabedian-Ruffalo, Susan M., Abu-Shakra, Susan, Beddingfield III, Frederick C.

“…Clinical trials demonstrate that onabotulinumtoxinA reduces upper limb post‐stroke spasticity, with therapeutic response influenced by injected dose…”
Get full text

Development and Validation of a Photographic Scale for Assessment of Lip Fullness by Werschler, W. Philip, Fagien, Steven, Thomas, Jane, Paradkar-Mitragotri, Deepali, Rotunda, Adam, Beddingfield, Frederick C.

“…Background As lip augmentation becomes more popular, validated measures of lip fullness for quantification of outcomes are needed. Objective Develop a scale…”
Get full text

Effectiveness of Juvéderm Ultra Plus Dermal Filler in the Treatment of Severe Nasolabial Folds by Lupo, Mary P., Smith, Stacy R., Thomas, Jane A., Murphy, Diane K., Beddingfield, Frederick C.

“…With the baby boomer generation firmly ensconced in middle age and the ubiquity of botulinum toxin type A, nonsurgical facial rejuvenation is becoming…”
Get full text

Juvederm ultra for lip enhancement: an open-label, multicenter study by Fagien, Steven, Maas, Corey, Murphy, Diane K, Thomas, Jane A, Beddingfield, 3rd, Frederick C

“…Juvéderm Ultra injectable gel (Allergan, Inc, Irvine, California) is approved in the United States to treat moderate to severe wrinkles and folds, such as…”
Get full text

Patient-reported outcomes of bimatoprost for eyelash growth: results from a randomized, double-masked, vehicle-controlled, parallel-group study by Fagien, Steven, Walt, John G, Carruthers, Jean, Cox, Sue Ellen, Wirta, David, Weng, Emily, Beddingfield, 3rd, Frederick C

“…Hypotrichosis of the eyelashes may negatively influence an individual's self-perception and appearance. Assessing the impact of treatment from a patient's…”
Get full text

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Repeated OnabotulinumtoxinA Treatments in Subjects With Crowʼs Feet Lines and Glabellar Lines by Carruthers, Jean, Rivkin, Alexander, Donofrio, Lisa, Bertucci, Vince, Somogyi, Chris, Lei, Xiaofang, Davis, Paula G, Campo, Antoinette, Beddingfield, Frederick C

“…BACKGROUNDThis is the third study in a Phase 3 program evaluating onabotulinumtoxinA treatment of crowʼs feet lines (CFL). OBJECTIVETo assess the efficacy and…”
Get full text

Long-term safety evaluation of bimatoprost ophthalmic solution 0.03%: a pooled analysis of six double-masked, randomized, active-controlled clinical trials by Wirta, David, Vandenburgh, Amanda M, Weng, Emily, Whitcup, Scott M, Kurstjens, Sef, Beddingfield, 3rd, Frederick C

“…Bimatoprost ophthalmic solution 0.03% was approved in the US for reducing intraoccular pressure (IOP) based on two double-masked, active-controlled clinical…”
Get full text

An Interrater and Intrarater Reliability Study of 3 Photographic Scales for the Classification of Perioral Aesthetic Features by Cohen, Joel L, Thomas, Jane, Paradkar, Deepali, Rotunda, Adam, Walker, Patricia S, Beddingfield, Frederick C, Philip, Asha, Davis, Paula G, Yalamanchili, Ramana

“…BACKGROUNDValidated aesthetic rating scales for the perioral area provide objective evaluations for clinical trials and practice. OBJECTIVETo confirm the…”
Get full text

Visual screening for malignant melanoma: a cost-effectiveness analysis by Losina, Elena, Walensky, Rochelle P, Geller, Alan, Beddingfield, 3rd, Frederick C, Wolf, Lindsey L, Gilchrest, Barbara A, Freedberg, Kenneth A

“…To evaluate the cost-effectiveness of various melanoma screening strategies proposed in the United States. We developed a computer simulation Markov model to…”
Get more information

Microdermabrasion: a review by Shpall, Rebecca, Beddingfield, 3rd, Frederick C, Watson, Deborah, Lask, Gary P

“…Microdermabrasion is used by clinicians and aestheticians worldwide to rejuvenate facial skin. The microdermabrator contains aluminum oxide or sodium chloride…”
Get more information

SYNERGY-1: A Phase 1, First-in-Human, Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics Study of KP104 in Escalating Single and Multiple Doses: SA-PO636 by Wabnitz, Paul, Gao, Xiang, Ma, Jay, Tsui, Ping, Rabe, Martin, Fu, Helen N., He, Chaomei, Wu, Jingtao, York, Brian K., Weng, Christina, Rankin, Jon, Beddingfield, Frederick C., Song, Wenru, Farinola, Nicholas, Lee, Richard

Get full text